Urinary markers in screening patients with hematuria

World Journal of Urology

Volumn 26, Issue 1, 2008, Pages 25-30

  Chiong, Edmund ^a   Gaston, Kris E ^a   Grossman, H Barton ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder cancer; Hematuria; NMP 22; Screening; Tumor markers; UroVysion

Indexed keywords

TUMOR MARKER;

ARTICLE; DIFFERENTIAL DIAGNOSIS; HEMATURIA; HUMAN; MASS SCREENING; METHODOLOGY; URINARY TRACT CANCER; URINE;

DIAGNOSIS, DIFFERENTIAL; HEMATURIA; HUMANS; MASS SCREENING; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS;

EID: 39349083726     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-007-0229-9     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 21:1315-1330
3. Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S (2002) Delay and survival in bladder cancer. BJU Int 89(9):868-878
4. Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB (2003) An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169(1):110-115
5. Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA Jr (2003) Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 170(4 Pt 1):1085-1087
6. Liedberg F, Anderson H, Mansson A, Mansson W (2003) Diagnostic delay and prognosis in invasive bladder cancer. Scand J Urol Nephrol 37(5):396-400
7. Grossfeld GD, Litwin MS, Wolf JS Jr, Hricak H, Shuler CL, Agerter DC, et al (2001) Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy-part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology 57(4):604-610
8. Glatz K, Willi N, Glatz D, Barascud A, Grilli B, Herzog M, et al (2006) An international telecytologic quiz on urinary cytology reveals educational deficits and absence of a commonly used classification system. Am J Clin Pathol 126(2):294-301
9. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al (2005) Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7):810-816
10. Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO (2006) Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176(1):44-47
11. Berezney R, Coffey DS (1974) Identification of a nuclear protein matrix. Biochem Biophys Res Commun 60(4):1410-1417
12. Fey EG, Bangs P, Sparks C, Odgren P (1991) The nuclear matrix: Defining structural and functional roles. Crit Rev Eukaryot Gene Expr 1(2):127-143
13. Getzenberg RH (1994) Nuclear matrix and the regulation of gene expression: Tissue specificity. J Cell Biochem 55(1):22-31
14. Miller TE, Beausang LA, Winchell LF, Lidgard GP (1992) Detection of nuclear matrix proteins in serum from cancer patients. Cancer Res 52(2):422-427
15. Khanuja PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, et al (1993) Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 53(14):3394-3398
16. Keesee SK, Meneghini MD, Szaro RP, Wu YJ (1994) Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci USA 91(5):1913-1916
17. Bidwell JP, Fey EG, van Wijnen AJ, Penman S, Stein JL, Lian JB, et al (1994) Nuclear matrix proteins distinguish normal diploid osteoblasts from osteosarcoma cells. Cancer Res 54(1):28-32
18. Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI, et al (1993) Nuclear matrix protein patterns in human benign prostate hyperplasia and prostate cancer. Cancer Res 53(4):744-746
19. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, et al (1996) Urinary nuclear matrix protein as a marker of transitional cell carcinoma of the urinary tract. J Urol 156(4):1280-1285
20. Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, et al (1996) Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156(2 Pt 1):363-367
21. Shariat SF, Casella R, Wians FH Jr, Ashfaq R, Balko J, Sulser T, et al (2004) Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 45(3):304-313
22. Shariat SF, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP (2003) The addition of urinary urokinasetype plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol 170(6 Pt 1):2244-2247
23. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, et al (2004) Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171(2 Pt 1):626-630
24. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A (1999) Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 162(1):53-57
25. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F (1999) Evaluation of NMP22 as a tumor marker in the detection of transitional cell carcinoma of the bladder. BJU Int 84(6):706-713
26. Sanchez-Carbayo M, Urrutia M, Silva JM, Romani R, De Buitrago JM, Navajo JA (2001) Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 165(5):1462-1467
27. Miyanaga N, Akaza H, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, et al (1999) Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int J Urol 6(4):173-177
28. Serretta V, Lo Presti D, Vasile P, Gange E, Esposito E, Menozzi I (1998) Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: Experience on 137 patients. Urology 52(5):793-796
29. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, et al (1998) Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 159(2):394-398
30. Casella R, Huber P, Blochlinger A, Stoffel F, Dalquen P, Gasser TC, et al (2000) Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: Experience with 130 patients with biopsy confirmed tumor. J Urol 164(6):1926-1928
31. Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Lüdecke G, et al (2006) Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 176 (3):919-926
32. Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A, et al (2001) Screening and monitoring for bladder cancer: Refining the use of NMP22. J Urol 166(1):75-78
33. Paoluzzi M, Cuttano MG, Mugnaini P, Salsano F, Giannotti P (1999) Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC) a study on patients with hematuria. Arch Ital Urol Androl 71(1):13-18
34. Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, et al (1997) [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer: Screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group]. Gan To Kagaku Ryoho 24(7):837-842
35. Oge O, Atsu N, Kendi S, Ozen H (2001) Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer. Int Urol Nephrol 32(3):367-370
36. Miyanaga N, Akaza H, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, et al (1999) Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int J Urol 6(4):173-177
37. Miyoshi Y, Matsuzaki J, Miura T (2001) [Evaluation of usefulness of urinary nuclear matrix protein 22 (NMP22) in the detection of urothelial transitional cell carcinoma]. Hinyokika Kiyo 2001 47(6):379-383
38. Lee MY, Tsou MH, Cheng MH, Chang DS, Yang AL, Ko JS (2000) Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma. World J Urol 18(6):401-405
39. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, et al (2000) A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164(5):1768-1775
40. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, et al (2002) Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168(5):1950-1954
41. Placer J, Espinet B, Salido M, Solé F, Gelabert-Mas A (2002) Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 42(6):547-552
42. Lotan Y, Svatek RS, Sagalowsky AI (2006) Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. Cancer 107(5):982-990
43. Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, et al (2006) Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107(9):2173-2179
44. Greene KL, Berry A, Konety BR (2006) Diagnostic utility of the ImmunoCyt/ uCyt+ test in bladder cancer. Rev Urol 8(4):190-197